VEGFA and glioblastoma: The authors, therefore, sought to test if the addition of an antimouse monoclonal VEGF antibody (B20, Genentech) to EGFRvIII CAR T-cell therapy in immunocompetent mouse models bearing orthotopic GBM cell lines that express EGFRvIII, CT2A and GSC005, could improve tumor infiltration of CAR-T cells [64].